Author:
Attwa Mohamed W.,Kadi Adnan A.,Darwish Hany W.,Alrabiah Haitham
Subject
Biochemistry, medical,Clinical Biochemistry,Biochemistry,General Medicine
Reference30 articles.
1. N-(5-chloro-1, 3-benzodioxol-4-yl)-7-[2-(4-methylpiperazin-1-yl) ethoxy]-5-(tetrahydro-2 h-pyran-4-yloxy) quinazolin-4-amine, a novel, highly selective, orally available, dual-specific c-Src/Abl kinase inhibitor;Hennequin;J. Med. Chem.,2006
2. Novel dual Src/Abl inhibitors for hematologic and solid malignancies;Schenone;Expert Opin. Investig. Drugs,2010
3. Anti-proliferative activity of c-Src kinase inhibitor saracatinib correlates with IGF1R and EGFR expression in ovarian cancer cell lines;Helfrich;Gynecol. Oncol.,2010
4. A phase Ib multiple ascending dose study of the safety, tolerability, and central nervous system availability of AZD0530 (saracatinib) in Alzheimer's disease;Nygaard;Alzheimers Res. Ther.,2015
5. A phase II study of saracatinib (AZD0530), a Src inhibitor, administered orally daily to patients with advanced thymic malignancies;Gubens;Lung Cancer,2015
Cited by
25 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献